Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Partitioning defective 3 protein (PAR-3)
- Target
- PAR-3
- Molecular classification
- Scaffold protein, Polarity complex component, Other (does not fit common therapeutic target classes like GPCR, enzyme, transporter)
01
Overview
Partitioning defective 3 protein (PAR-3) is a large, highly conserved scaffold protein containing three PDZ domains that coordinates the assembly of polarity protein complexes at specific membrane domains in animal cells. PAR-3 is essential for establishing and maintaining epithelial cell polarity, forming tight junctions, and regulating asymmetric cell division. It interacts extensively with Par6 and atypical protein kinase C (aPKC) within the tripartite PAR complex, orchestrating apical–basal polarity, cell–cell adhesion, and tight junction formation. In mammals, PAR-3 also plays a role in nuclear DNA repair pathways through direct interaction with the Ku70/Ku80 complex and DNA-dependent protein kinase in response to DNA damage. Dysregulation or mislocalization of PAR-3 has been implicated in cancer progression, with a dual role depending on the biological context.
- Other names
- PARD3Par3Partitioning defective 3 homologASIP (Atypical PKC-interacting protein; in vertebrates)Bazooka (Drosophila homolog)
02
Mechanism of action
Not applicable, as there are no approved drugs directly targeting PAR-3
03
Biological functions
Cell polarity establishment and maintenanceTight junction formation in epithelial cellsCell–cell adhesionSignal integration through protein–protein interactionsRegulation of DNA damage response and DNA repair (via interaction with Ku70/Ku80/DNA-PK complex)
04
Disease associations
Cancer (acts in both tumor suppression and promotion, context dependent)Immune response (through tight junction and epithelial barrier regulation)Other: Disruption linked to developmental defects due to loss of polarity and adhesion
05
Safety considerations
No direct safety concern from targeting (as it is not currently targeted by drugs).Hypothetical: Disruption of PAR-3 function leads to loss of cell polarity and tissue architecture, with possible tumor-promoting effects or developmental abnormalities, so direct inhibition might cause harm
06
Interacting drugs
None identified. There are currently no drugs that directly and specifically target PAR-3 in clinical or preclinical use; its function as a large, multi-domain scaffold limits druggability in the classical sense
07
Biomarkers
Altered PAR-3 expression or localization in tumors may serve as a biomarker of epithelial polarity status or some cancer subtypesFurther research may clarify additional biomarker roles, particularly in solid tumors
Beyond the preview
Go deeper on Partitioning defective 3 protein (PAR-3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Partitioning defective 3 protein (PAR-3).